| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-648SS | |||
| Azide and BSA Free | NBP2-81006 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-23484SS | |||
| Azide and BSA Free | NBP2-81015 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-05767SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-128SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-704SS | |||
| Azide and BSA Free | NBP2-80725 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77758-0.5mg | |||
| BSA Free | NB100-77758SS | |||
| Azide and BSA Free | NBP2-80627 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-89113-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-05119-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27392 | |||
| BSA Free | NBP2-27393SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-78259SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-59722SS | |||
| Azide and BSA Free | NBP2-80670 | |||
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0004.jpg "Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.")
![Western Blot: VEGF Antibody (VG76e) [NB100-648] - Analysis of VEGF in human kidney protein (30ug).](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Western-Blot-NB100-648-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: VEGF Antibody (VG76e) [NB100-648] - Immunofluorescent analysis of VEGF using NB100-648. This image submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunocytochemistry-Immunofluorescence-NB100-648-img0007.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC-P analysis of VEGF in sheep tonsil using NB100-648. This image was submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0006.jpg)
![Western Blot: Mouse Monoclonal VEGF Antibody (VG76e) [NB100-648] - Bone lysate homogenate from goats. SDS-PAGE with 0.3 mg of total protein from the homogenate per well. VEGF, NB100-648, was used at a dilution of 1:1000 in TBS Tween and 5% milk powder. The protein was labeled at 40 kDa. Quantification of VEGFA in bone graft in the tibia of intrailiac cellularized goats at different times compared with tibial autograft and untreated bone defect. Evaluation of pre-cellularized graft in iliac crest in the treatment of bone defects in the tibia of goats. G1: cellularized graft for 4 weeks applied to tibial bone defect, G2: cellularized graft for 6 weeks applied to tibial bone defect, G3: cellularized graft for 8 weeks applied to tibial bone defect, G4: tibial autograft and G5: untreated bone defect. All groups were evaluated 120 days after graft implantation. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-648_mouse-monoclonal-vegf-antibody-vg76e-western-blot-2952025142053..jpg)
![Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0014.jpg "<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - CAFs induced miR-33b downregulation and promoted the EMT phenotype in lung cancer cells. The protein expression levels of E-cadherin, Vimentin, ZEB1, Twist1 and Snail1 in the lung cancer cells co-cultured with CAFs were detected by immunoblotting, using GAPDH protein as the loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23082), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunocytochemistry-Immunofluorescence-NBP2-23484-img0009.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human cervical cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0006.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on U-87 cells with ZEB1 [2A8A6] Antibody NBP2-23484AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0012.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ZEB1 Antibody (2A8A6) [NBP2-23484] - ZEB1 expression was assayed in lung adenocarcinoma cells after transfectionwith miR-33b or miR-NC, anti-miR-33b or anti-miR-NC in H1299 and A549 cells. Image submitted by verified customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Western-Blot-NBP2-23484-img0013.jpg)
![Immunohistochemistry: ZEB1 Antibody (2A8A6) [NBP2-23484] - IHC analysis of paraffin-embedded human recturm cancer tissues with DAB staining.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Immunohistochemistry-NBP2-23484-img0004.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - Flow cytometric analysis of Hela cells using ZEB1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0007.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on with A549 cells with ZEB1 Antibody NBP2-23484PE and a a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0010.jpg)
![Flow Cytometry: ZEB1 Antibody (2A8A6) [NBP2-23484] - An intracellular stain was performed on Jurkat with ZEB1 Antibody (2A8A6) NBP2-23484 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse F(ab)2 IgG (H+L) PE-conjugated Antibody (R&D Systems, F0102B)](http://images.novusbio.com/fullsize/ZEB1-Antibody-2A8A6-Flow-Cytometry-NBP2-23484-img0011.jpg)
![Western Blot: DIO3 Antibody [NBP1-05767] - Detection of Dio3 in rat placenta.](http://images.novusbio.com/fullsize/DIO3-Antibody-Western-Blot-NBP1-05767-img0002.jpg "Western Blot: DIO3 Antibody [NBP1-05767] - Detection of Dio3 in rat placenta.")
![Flow Cytometry: DIO3 Antibody [NBP1-05767] - Analysis using the Biotin conjugate of NBP1-05767. Dio3 staining of mouse hepatic stellate cell cultured for 7 days. Image from verified customer review.](http://images.novusbio.com/fullsize/DIO3-Antibody-Flow-Cytometry-NBP1-05767-img0005.jpg)
![Western Blot: DIO3 Antibody [NBP1-05767] - Detection of Dio3 in rabbit brain whole cell homogenate. Photo courtesy of product review by verified customer.](http://images.novusbio.com/fullsize/DIO3-Antibody-Western-Blot-NBP1-05767-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-128] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti AHR [NB100-128] at a 1:100 dilution overnight at 4C and detected with an anti-goat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-128-img0004.jpg "Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-128] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti AHR [NB100-128] at a 1:100 dilution overnight at 4C and detected with an anti-goat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: AHR Antibody [NB100-128] - Analysis of FFPE human liver using 1:200 conc. of AHR antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunohistochemistry-Paraffin-NB100-128-img0006.jpg)
![Gel Super Shift Assays: AHR Antibody [NB100-128] - EMSA validation of AHR antibody on U937 cells nuclear protein. Image submitted by verified customer - see review for protocol details.](http://images.novusbio.com/fullsize/AHR-Antibody-Gel-Super-Shift-Assays-NB100-128-img0003.jpg)
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Cyto-histologic comparison of anti-ERCC1 immunoreactivity using the protocol 8F1 CC1-mono (top) or 8F1 H2-60 (bottom). Left: Pleural effusion sediment of lung adenocarcinoma. Right: thoracic lymph node. Arrow: Lymphocyte. Arrowhead: Streak of endothelial cells. Asterisk: Tumor cell cluster. 400 A- original magnification. Image collected and cropped by Citeab from the following publication (Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma (2011) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0004.jpg "Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Cyto-histologic comparison of anti-ERCC1 immunoreactivity using the protocol 8F1 CC1-mono (top) or 8F1 H2-60 (bottom). Left: Pleural effusion sediment of lung adenocarcinoma. Right: thoracic lymph node. Arrow: Lymphocyte. Arrowhead: Streak of endothelial cells. Asterisk: Tumor cell cluster. 400 A- original magnification. Image collected and cropped by Citeab from the following publication (Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma (2011) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Analysis of ERCC1 in human non-small cell lung cancer. Image courtesy of product review submitted by Alex Soltermann.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0002.jpg)
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Formalin fixed paraffin embedded human tonsil stained with ERCC1 antibody.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0003.jpg)
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Anti-ERCC1 immunohistochemistry on whole sections of a lung squamous cell carcinoma, using Mab 8F1 and D-10 with CC1-mono and H2-60 protocols. Note increased cytosolic background with H2-60. Arrow: Necrotic centre. Arrowhead: Stromal axis. 100 A- original magnification. Image collected and cropped by Citeab from the following publication (Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma (2011) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0005.jpg)
![Immunohistochemistry: ERCC1 Antibody (8F1) - BSA Free [NB500-704] - Anti-ERCC1 immunocytochemistry on cell block core of malignant pleural mesothelioma, using Mab 8F1 & D-10 with CC1-mono & H2-60 protocols. Arrow: Surrounding non-tumoral cells, including lymphocytes, macrophages & neutrophil granulocytes. Arrowhead: Unspecific plasma membrane staining with D-10. 200 × original magnification. Inset lower left: Staining of intracellular mucin vacuoles of a mucinous adenocarcinoma of unknown origin. 400 × original magnification. Image collected & cropped by CiteAb from the following publication (//jclinbioinformatics.biomedcentral.com/articles/10.1186/2043-9113-1-25), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-704_mouse-monoclonal-ercc1-antibody-8f1-310202415171338.jpg)
![Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Representative immunostaining of CD14 (red) in adult human lung tissue sample with nuclei counterstained blue. This image was submitted by customer review. Image from the Alexa Fluor 647 version of this antibody.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Immunocytochemistry-Immunofluorescence-NB100-77758-img0009.jpg "Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Representative immunostaining of CD14 (red) in adult human lung tissue sample with nuclei counterstained blue. This image was submitted by customer review. Image from the Alexa Fluor 647 version of this antibody.")
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - A surface stain was performed on human peripheral blood monocytes with CD163 (EDHu-1) antibody NB110-40686APC and a matched isotype control NBP2-27287APC. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. A co-stain was performed with NB100-77758AF488.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Human lung tissue was stained with FITC-conjugated CD14 (Green) for overnight. Image from the Alexa Fluor 488 version of this antibody.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Immunocytochemistry-Immunofluorescence-NB100-77758-img0008.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Human peripheral blood monocytes stained with M5E2 APC](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0001.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using the FITC conjugate of NB100-77758. Staining of Human peripheral blood monocytes with M5E2 FITC.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0004.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using the PE conjugate of NB100-77758. Staining of CD14 in human PBMC using anti-CD14 antibody conjugated with PE. Image from verified customer review.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0005.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using PE conjugate of NB100-77758. A cell surface stain was performed on hPBMCs with ILT5 antibody (MM0413-9S32) NBP2-11729 (top image) and a matched isotype control NBP2-27287 (bottom image). Cells were incubated in an antibody dilution of 1:200 for 20 minutes at room temperature. Both antibodies were conjugated to APC. A co-stain was performed using CD14 antibody (M5E2) NB100-77758PE.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0006.jpg)
![Dual RNAscope ISH-IHC: CD14 Antibody (M5E2) [NB100-77758] - TNFA mRNA (red) and CD14 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human malignant lymph node. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-TNFA and CD14 antibody (M5E2) at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Dual-RNAscope-ISH-IHC-NB100-77758-img0010.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NBP1-89113] - Staining in human endometrium and liver tissues . Corresponding FUS RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NBP1-89113-img0027.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: FUS Antibody [NBP1-89113] - Staining in human endometrium and liver tissues . Corresponding FUS RNA-seq data are presented for the same tissues.")
![<b>Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: FUS Antibody [NBP1-89113] - Analysis in U-251MG cells transfected with control siRNA, target specific siRNA probe #1 and #2, using anti-FUS antibody. Remaining relative intensity is presented. Loading control: anti-GAPDH.](http://images.novusbio.com/fullsize/FUS-Antibody-Western-Blot-NBP1-89113-img0029.jpg)
![Immunocytochemistry/Immunofluorescence: FUS Antibody [NBP1-89113] - Staining of human cell line U-251 MG shows localization to nucleoplasm. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-89113-img0028.jpg)
![Western Blot: FUS Antibody [NBP1-89113] - Analysis in mouse cell line NIH-3T3 and rat cell line NBT-II.](http://images.novusbio.com/fullsize/FUS-Antibody-Western-Blot-NBP1-89113-img0011.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NBP1-89113] - Staining of human cerebellum shows strong nuclear positivity in neuronal cells.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NBP1-89113-img0022.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NBP1-89113] - Staining of human colon shows strong nuclear positivity in glandular cells.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NBP1-89113-img0023.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NBP1-89113] - Staining of human endometrium shows strong nuclear positivity in glandular cells and stromal cells.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NBP1-89113-img0024.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NBP1-89113] - Staining of human liver shows moderate nuclear positivity in bile duct cells while hepatocytes are negative.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NBP1-89113-img0025.jpg)
![Immunohistochemistry-Paraffin: FUS Antibody [NBP1-89113] - Staining of human testis shows strong nuclear positivity in cells in seminiferous ducts.](http://images.novusbio.com/fullsize/FUS-Antibody-Immunohistochemistry-Paraffin-NBP1-89113-img0026.jpg)
![Western Blot: Collagen III alpha 1/COL3A1 Antibody (1E7-D7/Col3) - BSA Free [NBP1-05119] - Western blot analysis on total proteins extracted from cells cultured with L-PRP or P-PRP. Collagen I protein band was robust in the P-PRP-treated group; collagen III alpha 1 protein band was more abundant in the L-PRP-treated cells. Image collected and cropped by CiteAb from the following publication (//stemcellres.com/content/6/1/173) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-1E7-D7-Col3-BSA-Free-Western-Blot-NBP1-05119-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: Collagen III alpha 1/COL3A1 Antibody (1E7-D7/Col3) - BSA Free [NBP1-05119] - Western blot analysis on total proteins extracted from cells cultured with L-PRP or P-PRP. Collagen I protein band was robust in the P-PRP-treated group; collagen III alpha 1 protein band was more abundant in the L-PRP-treated cells. Image collected and cropped by CiteAb from the following publication (//stemcellres.com/content/6/1/173) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: Collagen III alpha 1/COL3A1 Antibody (1E7-D7/Col3) - BSA Free [NBP1-05119] - Human bronchus tissue](http://images.novusbio.com/fullsize/Collagen-III-alpha-1-COL3A1-Antibody-1E7-D7-Col3-BSA-Free-Immunohistochemistry-Paraffin-NBP1-05119-img0002.jpg)
![Western Blot: Rictor Antibody [NB100-611] - Detection of Human Rictor by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa and 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Rictor antibody NB100-611 used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/Rictor-Antibody-Western-Blot-NB100-611-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: Rictor Antibody [NB100-611] - Detection of Human Rictor by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa and 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Rictor antibody NB100-611 used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Immunoprecipitation: Rictor Antibody [NB100-611] - Detection of human Rictor by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Rictor antibody NB100-611 (lot 5) used for IP at 6 ug per reaction. Rictor was also immunoprecipitated by a previous lot of this antibody (lot 4) and rabbit anti-Rictor antibody NB100-612. For blotting immunoprecipitated Rictor, NB100-611 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/Rictor-Antibody-Immunoprecipitation-NB100-611-img0004.jpg)
![Simple Western: AG-2/AGR2 Antibody [NBP2-27393] - Analysis using the Azide Free version of NBP2-27393. Simple Western lane view shows a specific band for AGR2 in 0.5 mg/ml of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/AG-2-AGR2-Antibody-Simple-Western-NBP2-27393-img0008.jpg "Simple Western: AG-2/AGR2 Antibody [NBP2-27393] - Analysis using the Azide Free version of NBP2-27393. Simple Western lane view shows a specific band for AGR2 in 0.5 mg/ml of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![<b>Genetic Strategies Validation. </b>Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - Alterations of tumor-associated phenotypes in AG-2-silenced SNU-478 cells. AG-2 protein expression in SNU-478:VEC and SNU-478:KDs was detected by western blot analysis with beta-actin as a loading control. The result shown is a representative of three experiments. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-804), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/AG-2-AGR2-Antibody-Knockdown-Validated-NBP2-27393-img0013.jpg)
![Immunohistochemistry-Paraffin: AG-2/AGR2 Antibody [NBP2-27393] - Analysis using the Azide Free version of NBP2-27393. Staining of human adenocarcinoma of the colon stained with AGR2 antibody (2-5 ug/ml), peroxidase-conjugate and DAB chromogen. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/AG-2-AGR2-Antibody-Immunohistochemistry-Paraffin-NBP2-27393-img0004.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - AGR2 expression in cancer cell lines of the biliary tract. AGR2 mRNA levels in six biliary tract cancer cell lines were measured by real-time RT-PCR. The AGR2 transcript levels were normalized against those of the GAPDH. Results shown are means +/- standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression was detected by western blot analysis with beta-actin as a loading control. The result shown is a representative of three experiments. Abbreviations: CBD, common bile duct; GB, gall bladder; AoV, ampulla of Vater; IHD, intrahepatic duct; HDB, hepatic duct bifurcation; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated [24]. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-804), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/AG-2-AGR2-Antibody-Western-Blot-NBP2-27393-img0014.jpg)
![Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - Analysis using the Azide Free version of NBP2-27393. Detection of AGR2 using AGR2 antibody. MCF7 (A), Caco-2 (B) and human stomach lysate (C) probed with AGR2 antibody at 1:100. were used for this test. The higher molecular weight band of variable intensity at ~30 kDa is uncharacterized and may represent a form of AGR2.](http://images.novusbio.com/fullsize/AG-2-AGR2-Antibody-Western-Blot-NBP2-27393-img0009.jpg)
![Immunohistochemistry-Paraffin: AG-2/AGR2 Antibody [NBP2-27393] - Analysis using the Azide Free version of NBP2-27393. Staining of human adenocarcinoma of the breast stained with AGR2 antibody (2 ug/ml), peroxidase-conjugate and DAB chromogen. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/AG-2-AGR2-Antibody-Immunohistochemistry-Paraffin-NBP2-27393-img0003.jpg)
![Immunohistochemistry-Paraffin: AG-2/AGR2 Antibody [NBP2-27393] - Staining of AGR2 using AGR2 antibody. Formalin-fixed, paraffin-embedded normal colon tissue probed with AGR2 antibody at 1:100 dilution.](http://images.novusbio.com/fullsize/nbp2-27393_rabbit-polyclonal-ag-2-agr2-antibody-17720241044636.jpg)
![Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - AGR2 expression in cancer cell lines of the biliary tract. A. AGR2 mRNA levels in six biliary tract cancer cell lines were measured by real-time RT-PCR. The AGR2 transcript levels were normalized against those of the GAPDH. Results shown are means ± standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression was detected by western blot analysis with beta -actin as a loading control. The result shown is a representative of three experiments. Abbreviations: CBD, common bile duct; GB, gall bladder; AoV, ampulla of Vater; IHD, intrahepatic duct; HDB, hepatic duct bifurcation; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated [24]. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27393_rabbit-polyclonal-ag-2-agr2-antibody-310202415384191.jpg)
![Western Blot: AG-2/AGR2 Antibody [NBP2-27393] - Alterations of tumor-associated phenotypes by overexpression of AGR2 in SNU-869 cells. A. AGR2 expression in the SNU-869 stable transfectants was verified by real-time RT-PCR. The AGR2 transcript level was normalized against that of GAPDH. Results shown are means ± standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression in the SNU-869 stable transfectants was detected by western blot analysis with beta -actin as a loading control. The result shown is a representative of three experiments. C. Viability of the SNU-869 stable transfectants was measured by the MTT assay. Results shown are means ± standard deviations of three experiments (ANOVA P = 0.008; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.013). D. The effect of AGR2 overexpression on cell proliferation. Pulsed BrdU incorporation into the SNU-869 stable transfectants was measured by flow cytometry. Percentage of BrdU-positive cells was shown in mean ± standard deviation of four experiments (ANOVA P = 0.053; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.027). Results shown are representatives of four experiments. E. The effect of AGR2 overexpression on tumor cell invasion of SNU-869 cells. The numbers of invading cells in the transwell invasion assay were determined for SNU-869 stable transfectants. Results shown are means ± standard deviations of three experiments (ANOVA P = 0.003; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.026). Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-804), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27393_rabbit-polyclonal-ag-2-agr2-antibody-31020241613646.jpg)
![Immunohistochemistry: GLI-1 Antibody [NBP1-78259] - In vivo GLI1 expression after intratumoral administration of NVP-LDE225. LOX OMVI human melanoma cells were injected s.c into both flanks. Tumors were treated intratumorally on daily basis with vehicle (A & B) or NVP-LDE225 (C & D). Immunofluorescent microscopy of GLI1 was performed on isolated tumor tissues. GLI1 staining was performed by overnight incubation of sections at 4C with rabbit anti-GLI-1 polyclonal Ab or isotype control (A & C) followed by an 1 hr-incubation with AF488 Donkey IgG, anti-rabbit at RT (green). Counterstaining of nuclei was performed with propidium iodide (red). Pictures were taken on a confocal laser-scanning microscope system (LSM 410; Zeiss). Yellow color corresponds to double positive (anti-GLI1 and propidium iodide) nuclear staining. Image collected and cropped by CiteAb from the following publication (dx.plos.org/10.1371/journal.pone.0069064) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GLI-1-Antibody-Immunohistochemistry-NBP1-78259-img0009.jpg "<b>Biological Strategies Validation. </b>Immunohistochemistry: GLI-1 Antibody [NBP1-78259] - In vivo GLI1 expression after intratumoral administration of NVP-LDE225. LOX OMVI human melanoma cells were injected s.c into both flanks. Tumors were treated intratumorally on daily basis with vehicle (A & B) or NVP-LDE225 (C & D). Immunofluorescent microscopy of GLI1 was performed on isolated tumor tissues. GLI1 staining was performed by overnight incubation of sections at 4C with rabbit anti-GLI-1 polyclonal Ab or isotype control (A & C) followed by an 1 hr-incubation with AF488 Donkey IgG, anti-rabbit at RT (green). Counterstaining of nuclei was performed with propidium iodide (red). Pictures were taken on a confocal laser-scanning microscope system (LSM 410; Zeiss). Yellow color corresponds to double positive (anti-GLI1 and propidium iodide) nuclear staining. Image collected and cropped by CiteAb from the following publication (dx.plos.org/10.1371/journal.pone.0069064) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: GLI-1 Antibody [NBP1-78259] - Analysis of GLI-1 on partial recombinant GLI-1 protein (molecular weight of partial recombinant protein is 37 kDa).](http://images.novusbio.com/fullsize/GLI-1-Antibody-Western-Blot-NBP1-78259-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: GLI-1 Antibody [NBP1-78259] - GLI1 antibody was tested in HepG2 cells with FITC (green). Nuclei and actin were counterstained with DAPI (blue) and Phalloidin (red).](http://images.novusbio.com/fullsize/GLI-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-78259-img0006.jpg)
![Immunohistochemistry: GLI-1 Antibody [NBP1-78259] - Immunostaining of GLI-1 (green, indicated by arrows) in the suture mesenchyme of Bmpr1-alpha-fl/fl (control) and GLI1-CreERT2; Bmpr1-alpha-fl/fl (mutant) mice 2 weeks post induction (2 wpt). The inset shows the boxed region magnified. T tests were performed. *P < 0.05; **P < 0.01. Broken lines indicate the outline of the suture. Scale bars, 100 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41413-018-0031-x) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GLI-1-Antibody-Immunohistochemistry-NBP1-78259-img0010.jpg)
![Immunohistochemistry: GLI-1 Antibody [NBP1-78259] - Analysis of GLI-1 in mouse brain using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/GLI-1-Antibody-Immunohistochemistry-NBP1-78259-img0007.jpg)
![Immunocytochemistry/ Immunofluorescence: GLI-1 Antibody - BSA Free [NBP1-78259] - In vivo GLI1 expression after intratumoral administration of NVP-LDE225.LOX OMVI human melanoma cells were injected s.c into both flanks as mentioned above. Tumors were treated intratumorally on daily basis with vehicle (A & B) or NVP-LDE225 (C & D). Immunofluorescent microscopy of GLI1was performed on isolated tumor tissues. GLI1 staining was performed by overnight incubation of sections at 4°C with rabbit anti-human polyclonal Ab (B & D, NBP1-78259, Novus Biologicals, Littleton, CO) or isotype control (A & C) followed by an 1 hr-incubation with Alexa Fluor® 488 Donkey IgG, anti-rabbit (A21206, Invitrogen, Carlsbad, CA) at RT (green). Counterstaining of nuclei was performed with propidium iodide (red). Pictures were taken on a confocal laser-scanning microscope system (LSM 410; Zeiss). Yellow color corresponds to double positive (anti-GLI1 & propidium iodide) nuclear staining. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23935925), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-78259_rabbit-polyclonal-gli-1-antibody-3102024161607.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 increases p21, p53, and RB in HPV16- and 18-positive cancer. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-CIP2A and/or si-p53 were measured by Western blot analysis. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-80) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Knockdown-Validated-NB110-59722-img0013.jpg "<b>Genetic Strategies Validation. </b>Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 increases p21, p53, and RB in HPV16- and 18-positive cancer. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-CIP2A and/or si-p53 were measured by Western blot analysis. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-80) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Flow Cytometry: CIP2A Antibody (2G10) [NB110-59722] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using CIP2A antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Flow-Cytometry-NB110-59722-img0011.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - Detection of CIP2A in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Western-Blot-NB110-59722-img0004.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - Analysis of CIP2A in NIH/3T3 cell lysate.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Western-Blot-NB110-59722-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CIP2A Antibody (2G10) [NB110-59722] - CIP2A antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Immunocytochemistry-Immunofluorescence-NB110-59722-img0005.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody (2G10) [NB110-59722] - IHC analysis of formalin fixed paraffin-embedded (FFPE) human colon cancer using CIP2A antibody at 1:200 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Immunohistochemistry-Paraffin-NB110-59722-img0012.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 increases p21, p53, & RB in HPV16- & 18-positive cancer. (A) Protein levels of p21, p53, & RB in SiHa cells transfected w/ miR-375 inhibitor, -mimic, or NS control measured by Western blot analysis. 25%, 50%, 100% amounts of untreated cell lysates included to calibrate the semiquantitative measurement. (B) Relative endogenous mRNA levels of p21, p53, & RB measured in SiHa cells transfected w/ miR-375 inhibitor, -mimic, or NS control using qRT-PCR. (C) One hundred thousand SiHa cells seeded on 24-well plate & the number of cells counted by trypan blue exclusion staining assay 48 h post-transfection. (D) Protein levels of p21, p53, & RB in HeLa cells transfected w/ miR-375 inhibitor, -mimic, or NS control measured by Western blot analysis. (E) Relative p21 mRNA levels measured in HeLa cells transfected w/ miR-375 inhibitor, -mimic, or NS control. (F) Trypan blue exclusion staining assay used to analyze the proliferation rate of HeLa cells 48 h post-transcfection. (G) Flow cytometry analysis demonstrates G1 arrest of SiHa cells 48 h after transfection w/ miR-375-mimic compared to miR-375 inhibitor or NS control. (H) Protein levels of CIP2A, p53, & p21 in SiHa cells transfected w/ si-CIP2A and/or si-p53 measured by Western blot analysis. (I) Protein levels of CIP2A, p53, & p21 in SiHa cells transfected w/ si-p53 and/or miR-375-mimic measured by Western blot analysis. (J) mRNA levels of p21 in SiHa cells transfected w/ si-p53 and/or miR-375-mimic measured by qRT-PCR. The concentrations of siRNA or miRNA used in panels H, I, & J 10 nM & 25 nM, respectively. Results are expressed as mean ± SD from three independent experiments. *p < 0.05, ***p < 0.001, & ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-310202416205141.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 control on CIP2A-MYC pathway also contributes to p21 elevation. (A) p21, p53, RB, CIP2A, & MYC protein levels in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control were measured by Western blot analysis. Tubulin expression was used as internal control. 25%, 50%, 100% amounts of untreated cell lysates were included to calibrate the semiquantitative measurement. (B) Transfection with miR-375-mimic significantly upregulated p21 mRNA in MCF7. Relative endogenous p21 mRNA levels were measured in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control for 48 h using qRT-PCR. (C) CIP2A & MYC protein levels were effectively silenced by si-CIP2A transfection with 1 & 10 nM concentrations for 48 h. Increased p21 protein levels were detected in si-CIP2A dose-dependent manner. 10 nM of si-GFP was used as a control. (D) Protein levels of CIP2A, p53, & p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. (E) mRNA levels of p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by qRT-PCR. (F) Flow cytometry analysis demonstrates G1 arrest of MCF7 cells 48 h after transfection with miR-375-mimic compared to miR-375 inhibitor or NS control. The concentrations of siRNA or miRNA used in panels D, E, & F were 10 nM & 25 nM, respectively. (G) Schematic depiction of miR-375-mediated repression of CIP2A, E6, E6AP, & E7 in HPV16-positive cells that simultaneously increases tumor suppressor p53, p21, & RB, & causes cell cycle arrest. Results are expressed as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-310202416205185.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375-mediated repression of HPV16, E6AP, & CIP2A activates the p53-p21 network & suppresses telomerase activity. (A) miR-375 demonstrates upregulation of p53 & p21 comparable to that of the single or combined CIP2A, E6, & E6AP knockdown. CIP2A, E6AP, p53, & p21 protein levels in SiHa cells transfected with siRNA targeting CIP2A, HPV16-E6, & E6AP (si-CIP2A, si-E6, & si-E6AP, respectively) were analyzed by Western blot. 1 nM & 10 nM siRNA concentrations & 5 nM & 50 nM for miR-375-mimic were used for transfection. si-Three is a combination of the three siRNAs indicated above. 10 nM of si-GFP was used as a control. Tubulin expression was used as internal control. (B) The increase in p21 protein levels correlate to its mRNA levels. Relative endogenous p21 mRNA levels transfected with siRNAs or miR-375 were measured using qRT-PCR. (C) miR-375 exerted a similar or stronger reduction in TERT mRNA levels when compared to E6 & E6AP knockdown in SiHa cells. (D) SiHa cells transfected with miR-375-mimic significantly reduced telomerase activity. Relative telomerase activities in SiHa cells transfected with NS control, miR-375-mimic, & miR-375 inhibitor were measured by SYBR real-time PCR TRAP assay. Heat-inactivated telomerase extracts were used to normalize this data. *p < 0.05, **p < 0.01, ***p < 0.001, & ****p < 0.0001. ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-31020241620514.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 control on CIP2A-MYC pathway also contributes to p21 elevation. (A) p21, p53, RB, CIP2A, & MYC protein levels in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control were measured by Western blot analysis. Tubulin expression was used as internal control. 25%, 50%, 100% amounts of untreated cell lysates were included to calibrate the semiquantitative measurement. (B) Transfection with miR-375-mimic significantly upregulated p21 mRNA in MCF7. Relative endogenous p21 mRNA levels were measured in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control for 48 h using qRT-PCR. (C) CIP2A & MYC protein levels were effectively silenced by si-CIP2A transfection with 1 & 10 nM concentrations for 48 h. Increased p21 protein levels were detected in si-CIP2A dose-dependent manner. 10 nM of si-GFP was used as a control. (D) Protein levels of CIP2A, p53, & p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. (E) mRNA levels of p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by qRT-PCR. (F) Flow cytometry analysis demonstrates G1 arrest of MCF7 cells 48 h after transfection with miR-375-mimic compared to miR-375 inhibitor or NS control. The concentrations of siRNA or miRNA used in panels D, E, & F were 10 nM & 25 nM, respectively. (G) Schematic depiction of miR-375-mediated repression of CIP2A, E6, E6AP, & E7 in HPV16-positive cells that simultaneously increases tumor suppressor p53, p21, & RB, & causes cell cycle arrest. Results are expressed as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-31020241621848.jpg)